SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics reported highly encouraging initial Phase 1/2 data…

Tango Therapeutics, Inc. · 8-K filed Jun 8, 2026 at 07:15 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 8, 2026 at 07:15 ET

Tango Therapeutics reported highly encouraging initial Phase 1/2 data for vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib) in MTAP-deleted, RAS-mutant pancreatic cancer. The vopimetostat + daraxonrasib arm showed a 92% objective response rate (ORR) and a 90% six-month progression-free survival (PFS) rate in 12 evaluable second/third-line PDAC patients, with a manageable safety profile. The company plans to rapidly advance this combination into a Phase 3 randomized-controlled trial in front-line pancreatic cancer, subject to regulatory feedback.

  • Vopimetostat + daraxonrasib in 2/3L PDAC: 92% ORR (11/12 patients; 9 confirmed), 90% 6-month PFS rate, 100% DCR.
  • Vopimetostat + zoldonrasib in 2/3L PDAC: 52% ORR (14/27; 10 confirmed), 74% 6-month PFS rate, 96% DCR.
  • Combined ORR across both arms in PDAC: 64% (25/39 patients).
  • No discontinuations due to adverse events in either combination arm; no related Grade 4/5 AEs.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access